{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T13:49:00Z","timestamp":1776001740979,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1D1B03029399"],"award-info":[{"award-number":["2017R1D1B03029399"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015M3A9B6029138"],"award-info":[{"award-number":["2015M3A9B6029138"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["18182MFD410"],"award-info":[{"award-number":["18182MFD410"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","award":["CAP-12-2-KBSI"],"award-info":[{"award-number":["CAP-12-2-KBSI"]}],"id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205006","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T14:41:46Z","timestamp":1538664106000},"page":"e0205006","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-2915","authenticated-orcid":true,"given":"Yeongmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Young","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Keuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyuk-Jae","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geu-Ru","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Guk","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Won","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-3745","authenticated-orcid":true,"given":"Sang-Hak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2010.08.068","article-title":"Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg","volume":"213","author":"J Wi","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2011.12.042","article-title":"Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia","volume":"221","author":"SH Lee","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"AL Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"JB Christian","year":"2014","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy","volume":"19","author":"C Aguiar","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"R Ferrari","year":"2016","journal-title":"Eur Heart J Suppl"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","article-title":"Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia","volume":"10","author":"KC Maki","year":"2016","journal-title":"J Clin Lipidol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"TM Davis","year":"2011","journal-title":"Diabetologia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"G Yuan","year":"2007","journal-title":"CMAJ"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/clc.20830","article-title":"Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies","volume":"33","author":"CJ Pepine","year":"2010","journal-title":"Clin Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.atherosclerosis.2015.06.012","article-title":"Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature","volume":"242","author":"MK Ito","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ijcard.2016.06.234","article-title":"Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment","volume":"221","author":"S Zhao","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5551\/jat.35626","article-title":"Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study","volume":"24","author":"S Oikawa","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e0116513","DOI":"10.1371\/journal.pone.0116513","article-title":"Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan","volume":"10","author":"LT Ho","year":"2015","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/ATVBAHA.107.140103","article-title":"Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study","volume":"27","author":"CQ Lai","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.ejhg.5202003","article-title":"The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment","volume":"16","author":"JA Smith","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/FPC.0000000000000219","article-title":"A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies","volume":"26","author":"MR Irvin","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cpt.798","article-title":"Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes","volume":"103","author":"DM Rotroff","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10557-012-6394-0","article-title":"A review of time courses and predictors of lipid changes with fenofibric acid-statin combination","volume":"26","author":"TD Filippatos","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","article-title":"Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study","volume":"235","author":"S Zhao","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"DM Mann","year":"2010","journal-title":"Ann Pharmacother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s00125-014-3344-3","article-title":"Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"57","author":"MC d\u2019Emden","year":"2014","journal-title":"Diabetologia"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.113.005757","article-title":"Racial\/ethnic differences in dyslipidemia patterns","volume":"129","author":"AT Frank","year":"2014","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"SM Grundy","year":"2004","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"R Ferrari","year":"2016","journal-title":"Eur Heart J Suppl"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 \u2013executive summary","volume":"8","author":"TA Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/ATVBAHA.113.302926","article-title":"Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)","volume":"34","author":"MH Davidson","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.pcad.2013.02.001","article-title":"Adherence to cardiovascular medications: lessons learned and future directions","volume":"55","author":"IM Kronish","year":"2013","journal-title":"Prog Cardiovasc Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280050124","article-title":"Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia","volume":"50","author":"T Sudhop","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg HN ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T04:54:53Z","timestamp":1540270493000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205006"}},"subtitle":[],"editor":[{"given":"Laura","family":"Calabresi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205006","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]}}}